Literature DB >> 17923280

Translational control: a target for cancer therapy.

Saritha C Thumma1, Robert A Kratzke.   

Abstract

Cap-mediated translation is the default mechanism for the synthesis of proteins in eukaryotic cells. Increasingly, malignant cells have been found to have deregulation of this process. Return of normal translational control is associated with loss of tumorigenic potential in pre-clinical models. Currently, a variety of novel therapeutics are in development targeting this mechanism as a treatment for cancer.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17923280     DOI： 10.1016/j.canlet.2007.08.022

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  19 in total

1.  Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.

Authors:  Yikun Li; Ping Yue; Xingming Deng; Takeshi Ueda; Rikiro Fukunaga; Fadlo R Khuri; Shi-Yong Sun
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.

Authors:  Zhijiu Zhong; Wen-Shuz Yeow; Chunhua Zou; Richard Wassell; Chenguang Wang; Richard G Pestell; Judy N Quong; Andrew A Quong
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 3.  Translational control in cancer.

Authors:  Deborah Silvera; Silvia C Formenti; Robert J Schneider
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

Review 4.  Targeting eukaryotic protein translation in mesothelioma.

Authors:  Robert A Kratzke
Journal:  Transl Lung Cancer Res       Date:  2017-06

5.  The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.

Authors:  Songqing Fan; Yikun Li; Ping Yue; Fadlo R Khuri; Shi-Yong Sun
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

6.  Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E.

Authors:  Yuqing Ge; Rubin Cheng; Yuhong Zhou; Jianping Shen; Laijun Peng; Xiaofeng Xu; Qun Dai; Pei Liu; Haibing Wang; Xiaoqiong Ma; Jia Jia; Zhe Chen
Journal:  Mol Cell Biochem       Date:  2012-05-22       Impact factor: 3.396

7.  Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.

Authors:  Esther Z Chen; Blake A Jacobson; Manish R Patel; Aniekan M Okon; Shui Li; Kerry Xiong; Abhishek J Vaidya; Peter B Bitterman; Carston R Wagner; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2014-04-09       Impact factor: 3.850

8.  Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.

Authors:  Yikun Li; Songqing Fan; Junghui Koo; Ping Yue; Zhuo Georgia Chen; Taofeek K Owonikoko; Suresh S Ramalingam; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Biol Ther       Date:  2012-03-01       Impact factor: 4.742

9.  Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.

Authors:  Songqing Fan; Suresh S Ramalingam; John Kauh; Zhiheng Xu; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Biol Ther       Date:  2009-08-08       Impact factor: 4.742

10.  Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

Authors:  B A Jacobson; A De; M G Kratzke; M R Patel; J Jay-Dixon; B A Whitson; A A Sadiq; P B Bitterman; V A Polunovsky; R A Kratzke
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.